Table 2.

Median values of kidney injury biomarkers: HIV-positive patients with HIVAN and other cohortsa

NGAL (μg/g creatinine)Serum Creatinine (mg/dl)GFR (ml/min)Protein/Creatinine Ratio
Control, HIV-positive, race-matched (n = 24)28 (4–481)c0.9 (0.4–1.2)c116 (83–251)c0.0 (0.0–0.0)
Control, HIV-positive, non-race-matched (n = 14)74 (5–361)0.8 (0.4–1.0)c114 (83–246)c0.0 (0.0–0.3)c
CKD, HIV-positive, HIVAN (n = 13)231 (18–4050)2.6 (0.9–18.5)30 (4–117)0.6 (0.0–9.6)
CKD, HIV-positive, race-matched (n = 6)88 (5–374)2.1 (1.1–3.4)37 (24–190)0.2 (0.0–8.2)
CKD, HIV-positive, non-race-matched (n = 10)51 (19–225)1.5 (0.3–2.2)57 (13–344)0.5 (0.0–9.2)
CKD, HIV-negative (n = 106)12 (1–344)c1.5 (1–12.6)43 (5–90)N/A
CKD, HIV-negative, membranous (n = 16)8 (1–248)c1.3 (0.5–3.2)b56 (21–128)4.5 (1.0–15.3)b
CKD, HIV-negative, FSGS (n = 7)19 (4–67)b1.2 (1.1–3.7)73 (17–63)1.9 (1.0–2.4)
CKD, HIV-negative, diabetic and hypertensive kidney diseases (n = 12)32 (2–316)b2.7 (0.7–3.6)26 (18–98)2.3 (0.2–27.9)
AKI, all causes (n = 30)296 (11–1833)3.9 (0.7–28.6)16 (2–53)N/A
  • aAll data presented as median (range). N/A, not available.

  • bP value <0.05 in comparison with the HIVAN cohort.

  • cP value <0.01 in comparison with the HIVAN cohort.